个人简历

学习及工作经历： 1995年～2000年 广西医科大学临床医学系 2004年～2007年 中山大学附属肿瘤医院内科攻读肿瘤学硕士 2007年～2010年 中山大学附属肿瘤医院内科肿瘤学专科培训医师 2010年～2016年 中山大学附属肿瘤医院内科主治医师，并获博士学位 2015年～2017年 美国加州大学圣地亚哥分校访问学者 2017年至今 中山大学附属肿瘤医院内科副主任医师

研究领域

消化系统肿瘤（食管癌、胃癌、肠癌、胰腺癌、胆管癌、胃肠胰神经内分泌肿瘤等）的治疗与研究

近期论文

1.Xu RH, Wei W, Krawczyk M, Wang W, Luo H（co-first author）et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nature Materials 16, 1155–1161 (2017) doi:10.1038/nmat4997（SCI 39.7） 2.Luo HY, Li Y, Wang W et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol. 27: 1074–1081, 2016. （SCI 11.9） 3.Hao X, Luo H（co-first author）, Krawczyk M, Wei W, et al. DNA methylation markers for diagnosis and prognosis of common cancers. Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):7414-7419. doi: 10.1073/pnas.1703577114. （SCI 9.7） 4.Luo HY, Xu RH. Reply to “Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients” Ann Oncol. 2016 May 18. pii: mdw212. [Epub ahead of print]（SCI 11.9） 5.Wei XL, Luo HY（co-first author）, Li CF, et al. Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers. Int J Cancer. 2017 Jul 1;141(1):152-159. doi: 10.1002/ijc.30719 （SCI 6.5） 6.Zeng ZL, Luo HY（co-first author）, Yang J, Wu WJ, Chen DL, Huang P, Xu RH*. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res. Feb 15;20(4):1042-52, 2014. (SCI 9.6) 7.Zhang Y, Luo HY（co-first author）, Liu GL, Wang DS, Wang ZQ, Zeng ZL, Xu RH*. Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor overexpression in human pancreatic carcinoma. Int J Oncol. 2014 Oct 17. doi: 10.3892/ijo.2014.2709. (SCI 3.09) 8.Luo HY, Xu RH. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol. 2014 Apr 14;20(14):3858-74.(SCI 3.36) 9.Luo HY, Wang ZQ, Wang FH, Qiu MZ, Teng KY, Ruan DY, He YJ, Li YH, Xu RH*. Phase II study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer. Am J Clin Oncol. Dec;34(6):555-60, 2011. (SCI 3.25) 10.Li YH, Luo HY（co-first author），Wang FH, Wang ZQ, Qiu MZ, Shi YX, Xiang XJ, Chen XQ, He YJ, Xu RH*. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. Apr;136(4):503-10. 2010 (SCI 3.5)